Gold G, Giannakopoulos P, Montes-Paixao Júnior C, Herrmann F R, Mulligan R, Michel J P, Bouras C
Department of Geriatrics, University Hospital of Genèva, Switzerland.
Neurology. 1997 Sep;49(3):690-4. doi: 10.1212/wnl.49.3.690.
The objective of this study was to determine the sensitivity and specificity of clinical criteria for possible vascular dementia (VaD) recently developed independently by two groups: the State of California Alzheimer's Disease Diagnostic and Treatment Centers (ADDTC) and the National Institute for Neurological Disorders and Stroke with the Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN). We also wished to compare the performance of the new criteria to that of the Hachinski Ischemic Score (HIS). The study was comprised of a retrospective chart review and clinicopathologic correlation, and took place in 304-bed acute-care geriatric hospital. The subjects were 113 autopsied elderly patients with dementia, who were assessed to determine sensitivity and specificity of the ADDTC and NINDS-AIREN criteria for possible VaD. Sensitivity and specificity were calculated using the neuropathologic diagnosis as a gold standard. Sensitivity was 0.63, and specificity was 0.64 for the ADDTC, 0.58 sensitivity and 0.80 specificity for the NINDS, and 0.43 sensitivity and 0.88 specificity for the HIS. Test combinations did not lead to substantial gains in sensitivity or specificity. The majority of patients with Alzheimer's disease were successfully excluded by the ADDTC (87%), the NINDS-AIREN (91%), and the HIS (97%). The proportion of mixed dementia cases clinically misclassified as VaD was 54% for the ADDTC, 29% for the NINDS-AIREN, and 18% for the HIS. Low sensitivity is the main weakness of the above clinical criteria for possible VaD. Mixed dementia is better excluded by the NINDS-AIREN than the ADDTC. Data from this validation study should provide valuable information to clinicians and researchers who wish to apply these criteria to the diagnosis of VaD.
本研究的目的是确定近期由两个小组独立制定的可能血管性痴呆(VaD)临床标准的敏感性和特异性:加利福尼亚州阿尔茨海默病诊断与治疗中心(ADDTC)以及美国国立神经疾病与中风研究所和国际神经科学研究与教学协会(NINDS-AIREN)。我们还希望将新标准的性能与哈金斯基缺血评分(HIS)的性能进行比较。该研究包括回顾性病历审查和临床病理相关性分析,在一家拥有304张床位的急性护理老年医院进行。研究对象为113例经尸检的老年痴呆患者,对其进行评估以确定ADDTC和NINDS-AIREN可能VaD标准的敏感性和特异性。以神经病理学诊断作为金标准计算敏感性和特异性。ADDTC的敏感性为0.63,特异性为0.64;NINDS的敏感性为0.58,特异性为0.80;HIS的敏感性为0.43,特异性为0.88。测试组合并未在敏感性或特异性方面带来显著提高。ADDTC(87%)、NINDS-AIREN(91%)和HIS(97%)成功排除了大多数阿尔茨海默病患者。ADDTC将临床误诊为VaD的混合性痴呆病例比例为54%,NINDS-AIREN为29%,HIS为18%。低敏感性是上述可能VaD临床标准的主要弱点。NINDS-AIREN比ADDTC能更好地排除混合性痴呆。来自这项验证研究的数据应为希望将这些标准应用于VaD诊断的临床医生和研究人员提供有价值的信息。